1	FRONT MATTER
2 3	Title
4 5 6	CAR Density Influences Antitumoral Efficacy of BCMA CAR T cells and Correlates with Clinical Outcome
7 8 9	Short Title
10 11	CAR density influences CAR T cell efficacy
11	
13	Authors
14	
15	Paula Rodriguez-Marquez ^{1,†} , Maria E. Calleja-Cervantes ^{1,2,†} , Guillermo Serrano ^{2,†} , Aina Oliver-
16	Caldes ³ , Maria L. Palacios-Berraquero ⁴ , Angel Martin-Mallo ¹ , Cristina Calviño ⁴ , Marta Español-
17	Rego ⁵ , Candela Ceballos ⁶ , Teresa Lozano ⁷ , Patxi San Martin-Uriz ¹ , Amaia Vilas-Zornoza ^{1,10} ,
18	Saray Rodriguez-Diaz ¹ , Rebeca Martinez-Turrillas ^{1,10} , Patricia Jauregui ⁴ , Diego Alignani ⁸ , Maria
19 20	C. Viguria ⁶ , Margarita Redondo ⁶ , Mariona Pascal ⁵ , Manel Juan ⁵ , Alvaro Urbano-Ispizua ³ , Paula Rodriguez-Otero ⁴ , Ana Alfonso-Pierola ^{4,10} , Bruno Paiva ^{1,8,10} , Juan Jose Lasarte ⁷ , Susana
20 21	Inoges ^{4,9,10} , Ascension Lopez-Diaz de Cerio ^{4,9,10} , Jesus San-Miguel ^{1,4,10} , Carlos Fernandez de
21	Larrea ³ , Mikel Hernaez ^{2,10,11,‡,*} , Juan R. Rodriguez-Madoz ^{1,10,‡,*} , Felipe Prosper ^{1,4,10,‡,*}
22	Lanca, wiker nemacz w , juan K. Kounguez-wiadoz w , renpe i tosper
24	Affiliations
25	
26 27	¹ Hemato-Oncology Program. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain. ² Computational Biology Program. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain.
28 29	³ Department of Hematology. Hospital Clinic de Barcelona. IDIBAPS. Universidad de Barcelona. Barcelona, Spain
30 31	⁴ Hematology and Cell Therapy Department. Clínica Universidad de Navarra, CUN. Pamplona, Spain.
32 33	⁵ Department of Immunology. Hospital Clinic de Barcelona. IDIBAPS. Universidad de Barcelona. Barcelona, Spain.
33 34	⁶ Hematology Service. Hospital Universitario de Navarra. IdiSNA. Pamplona, Spain.
35 36	⁷ Immunology and Immunotherapy Program. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain.
30 37	⁸ Flow Cytometry Core. Cima Universidad de Navarra. IdiSNA. Pamplona, Spain.
38	⁹ Immunology and Immunotherapy Department. Clínica Universidad de Navarra, CUN. Pamplona,
39	Spain.
40	¹⁰ Centro de Investigación Biomédica en Red de Cáncer (CIBERONC). Madrid, Spain.
41	¹¹ Data Science and Artificial Intelligence Institute (DATAI). Universidad de Navarra. Pamplona,
42	Spain.
43	
44	
45	*Corresponding author. Email: <u>mhernaez@unav.es; jrrodriguez@unav.es; fprosper@unav.es</u>
46	†These authors contributed equally to this work
47	‡These authors share senior authorship
48	

49 ABSTRACT

50

Identification of new markers associated with long-term efficacy in patients treated with CAR T 51 cells is a current medical need, particularly in diseases such as multiple myeloma. In this study we 52 address the impact of CAR density on the functionality of BCMA-CAR T cells. Functional and 53 transcriptional studies demonstrate that CAR T cells with high expression of the CAR construct 54 show an increased tonic signaling with upregulation of exhaustion markers, increased in vitro 55 cytotoxicity but a decrease in *in vivo* BM infiltration. Characterization of Gene Regulatory 56 Networks using scRNA-seq identified regulons associated to activation and exhaustion upregulated 57 in CAR^{High} T cells, providing mechanistic insights behind differential functionality of these cells. 58 Finally, we demonstrate that patients treated with CAR T cell products enriched in CAR^{High} T cells 59 show a significantly worse clinical response in several hematological malignancies. In summary, 60 our work demonstrates that CAR density plays an important role in CAR T activity with significant 61 impact on clinical response. 62

63

64 **Teaser**

High CAR molecule density affects CAR T cell activity and associates with impaired clinicalresponse.

67

07

69 **INTRODUCTION**

Chimeric antigen receptor (CAR) T cell therapies have emerged as a promising therapeutic tool 70 against cancer, revolutionizing cancer immunotherapy (1). Second-generation CAR T cells have 71 shown to induce impressive clinical responses in hematological malignancies, such as 72 chemotherapy-resistant B cell leukemias and lymphomas (2-4) and multiple myeloma (MM) (5-73 7). Despite the high rates of remissions, not every patient achieves a complete response after CAR 74 T-cell therapy. In addition, a significant number of patients experience a relapse of the disease. 75 Particularly in patients with MM, despite their impressive responses, apparently, so far there is no 76 a plateau in the survival curves after CAR T cell therapy (5-7), which contrast with results obtained 77 with CD19 CAR T cells in acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphomas 78 79 (NHL).

It is well known that CAR T cells are heterogeneous products with multiple factors contributing to 80 their efficacy. Several studies have demonstrated how extrinsic factors, like antigen density or 81 82 tumor burden, strongly influence efficacy of CAR T cells (8, 9). In addition, factors related to CAR structure, like the costimulatory domain or the hinge length, can also affect the antitumoral 83 potential of CAR T cells (10-12). Moreover, intrinsic cell factors, such as the differentiation state 84 of T cells, the CD4/CD8 ratio or the T cell polyfunctionality have been correlated with the 85 86 therapeutic efficacy and has led to the hypothesis that enrichment of CAR T cell products in T cells with a more immature phenotype may be associated with improvement in long term responses (13– 87 16). On the other hand, an increase in T cells with an effector or exhausted phenotype may result 88 in a reduced persistence of CAR T cells with a decrease in clinical response (13). Previous studies 89 90 identified that CAR signaling in the absence of antigen stimulation, denominated tonic signaling, is associated to early T cell exhaustion (17–20), suggesting its role in triggering premature T-cell 91 92 dysfunction. Additional factors related to the CAR construct may have an impact on functionality. For instance, recent studies have demonstrated that a more physiological expression of the CAR, 93 by the integration of the transgene in the TRAC locus or the use of different promoters, can be 94 associated with improved efficacy and reduced toxicity (21-23). These results also suggest that the 95 density of CAR molecule in the membrane of CAR T cells might influence CAR signaling, 96 affecting their antitumoral efficacy (23, 24). However, this hypothesis and the impact on clinical 97 efficacy has not been formally explored. 98

Technological advances in genomics, such as single-cell sequencing, have allowed a notable 99 progress towards understanding the genomic landscape of CAR T cells, providing some 100 mechanistic insights into proper CAR T cell function (25-29). Moreover, functional commitment of 101 CAR T cells is governed by complex Gene Regulatory Networks (GRN) that control CAR T cells 102 at baseline as well as CAR T cell dynamics after antigen recognition being essential for CAR T 103 functionality (30). Using scRNA-seq, recent studies have identified specific T cell signatures 104 associated with efficacy and toxicity in patients with large B cell lymphomas (26), or molecular 105 determinants of CAR T cell persistence such as IRF7 mediated regulation of chronic interferon 106 107 signaling (29), establishing this technology as a useful tool to improve efficacy of CAR T.

In this study, we address the impact of CAR density on the functionality of BCMA-CAR T cells. 108 Phenotypic, functional, transcriptomic and epigenomic studies at bulk and single cell level revealed 109 different profiles between CAR T cells with high and low expression of the CAR molecule 110 (CAR^{High} and CAR^{Low} T cells). We show that CAR^{High} T cells are associated with tonic signaling 111 and an exhausted phenotype, and identify the molecular mechanisms involved in the different 112 functionality of CAR^{High} and CAR^{Low} T cells. We define a molecular signature associated with 113 increase CAR density that, when applied to CAR T cell products, may predict clinical response. 114 115 These results would provide a useful tool to understand the mechanisms behind proper CAR T cell function and identify biomarkers of response with potential clinical implications. 116

118 **RESULTS**

119 CAR T cells exhibit a wide range of CAR density on cell surface that influences CAR 120 mediated signaling

Current CAR T cell products are generated using retro/lentiviral vectors that render different levels 121 122 of transduction and transgene expression within the cells, and consequently a wide range distribution in the number of CAR molecules in the surface of transduced cells. We hypothesized 123 that this heterogeneity in CAR density could affect CAR-mediated signaling, and hence, influence 124 the efficacy of CAR T cell products. To address this question, we first used a triple parameter 125 reporter (TPR) system in Jurkat cells (31) to measure, by flow cytometry, CAR-mediated activation 126 of the main signaling pathways (NFAT, NFkB and AP1) after tumor recognition using CAR T cells 127 with different levels of CAR on the cell surface. Jurkat-TPR cells were infected with a second-128 generation CAR construct targeting BCMA, with 4-1BB as costimulatory domain, that was further 129 modified to include a EGFRt reporter, facilitating the measurement of CAR level (Fig. S1). Then, 130 subsets of Jurkat-TPR cells presenting different levels of CAR (termed CAR^{High} and CAR^{Low} cells) 131 were selected according to the fluorescence intensity (FI) of EGFRt (top and bottom FI quartiles 132 respectively, see methods), and analyzed after coculture with different BCMA-expressing MM cell 133 lines (Fig. S1). We observed significantly increased levels of activation in the three mentioned 134 pathways within the CAR^{High} population. Moreover, a significant increase of activation of CAR^{High} 135 cells was also observed even in the absence of tumor cells, indicating an increase in tonic signaling 136 at baseline (Fig. S1). We consistently observed this functional pattern with other CAR constructs 137 targeting CD19, CD33 and HER2 (Fig. S1), indicating that a higher density of CAR molecules in 138

the cell surface increases both the tonic signaling as well as the signal transduction after tumor

140 encountering.

141 CAR density influences antitumoral response of CAR T cells targeting BCMA

To further analyze the effect of CAR density on antitumoral efficacy, we characterized CAR T 142 cells from ten healthy donors that were generated using a BCMA-targeting CAR construct (derived 143 from ARI-0002h) co-expressing BFP as reporter marker (Fig. S2). CAR T cells were sorted into 144 CAR^{High} and CAR^{Low} subpopulations based on the expression of BFP (Fig. 1A and S3). CAR^{High} 145 T cells include those cells with a BFP FI > 1.2×10^4 (average FI 26861 ± 5795), while the CAR^{Low} 146 T cells subpopulation was restricted to BFP FI < $4x10^3$ (average FI 2513 ± 388). These FI values 147 corresponded to the top and bottom FI quartiles respectively (Fig. S3). Then, BFP FI values were 148 used to quantify the number of CAR molecules on the surface of these two CAR T cell 149 subpopulations using an antibody-binding capacity bead assay. CAR^{High} T cells presented more 150 than 5000 CAR molecules/cell, while the number of molecules/cell in CAR^{Low} T cells was below 151 1500 (Fig. S3). Vector copy number analysis revealed a significant higher number of viral 152 integrations within CAR^{High} T cells, with an average of 4.5 ± 1.3 integrations in CAR^{High} T cells vs 153 1.8 ± 0.3 in CAR^{Low} T cells, and a significant increase in CAR mRNA expression levels was also 154 observed, which could explain the increased CAR density observed in these cells (Fig. S3). We 155 found increased cytotoxic activity and greater levels of IFN-y, IL-2 and TNFa production in 156 CAR^{High} T cells (Fig. 1B-C). To determine the translational value of these findings, we examined 157 CAR T cell levels in CAR T cell products from an academic clinical trial (CARTBCMA-HCB-01; 158 NCT04309981) (Fig. S3). We observed an increased in vitro lytic activity in those CAR T cell 159 products enriched in CAR^{High} T cells (>30% of cells with >5000 CAR molecules/cell) (Fig. 1D). 160

161 Next, we analyzed the phenotype of CAR^{High} and CAR^{Low} T cells before and after stimulation with 162 tumor cells (Fig. 1E and S4). At baseline, we observed a statistically significant enrichment of 163 central memory (T_{CM}) and effector memory (T_{EM}) phenotypes within CAR^{High} T cells, with 164 concomitant reduction of naïve (T_N) and stem central memory (T_{SCM}) cells in both CD4⁺ and CD8⁺ 165 subsets. After antigen stimulation, both populations acquired a T_{EM} -T_E phenotype, although

increased numbers of T_E were observed in CAR^{High} T cells (Fig. 1E and S4). These results suggest a higher degree of differentiation in CAR^{High} T cells even in the absence of antigen stimulation. Moreover, we observed that CAR^{High} T cells presented an increase in basal activation, with significant higher levels of HLA-DR⁺ and CD137⁺ cells, along with a higher percentage of CD8⁺ T cells currently on more merilem of subcurrent of automation (LAC2, TIM2 and/or PD1)

T cells expressing a combination of two or more markers of exhaustion (LAG3, TIM3 and/or PD1) (Fig. 1F-H). These differences in cell exhaustion increased after antigen stimulation, with more

than 30% of CD8⁺ CAR^{High} T cells expressing an exhausted phenotype (Fig. 1H).

To determine whether different CAR densities would affect long-term antitumor potential, we 173 evaluated their efficacy in vivo using a stress test in NSG mice (21, 32). ARP-1 cells expressing 174 luciferase (1x10⁶ cells/animal) were transplanted in NSG mice and after 6 days 0.5x10⁶ CAR^{High} T 175 or CAR^{Low} T cells FACS-sorted from a BCMA-CAR T cells were infused into the animals (Fig. 176 2A). Both subpopulations were able to eradicate tumor cells and increase survival of treated 177 animals as demonstrated by luciferase measurements and by quantification of tumor cells into the 178 bone marrow 28 days after treatment (Fig. 2B-E). However, when we analyzed the infiltration of 179 CAR T cells in the bone marrow of the animals after 28 days, we observed a statistically significant 180 reduction in the number of CAR T cells in animals treated with CAR^{High} T cells in comparison with 181 CAR^{Low} T cells, suggesting a lower persistence of CAR^{High} T (Fig. 2F). Overall, these results 182 indicate that CAR^{High} T cells show increased activation and tonic signaling and a more exhausted 183 phenotype associated with an increase in *in vitro* cytotoxicity but a decrease in CAR T cell 184

185 persistence in BM which could have an impact on the clinical response.

186 CAR^{High} T cells display different transcriptomic and chromatin landscape with increased 187 tonic signaling and T cell activation

Given the differences observed in phenotype and persistence between CAR^{High} T and CAR^{Low} T 188 cells, we delved into the transcriptomic and epigenetic landscape of the two subpopulations of CAR 189 T cells. Sorted CD4⁺ and CD8⁺ CAR^{High} and CAR^{Low} T cell populations from six different CAR T 190 cell productions were profiled using high-throughput RNA sequencing (RNA-seq) and assay for 191 transposase-accessible chromatin (ATAC-seq). Transcriptomic analysis revealed less than 100 192 genes differentially expressed (DEGs, FDR<0.05, Log2FC>2) between CAR^{High} T and CAR^{Low} T 193 (Table S1). Similarly, the analysis of the ATAC-seq data revealed: i) a similar peak distribution in 194 both populations, with >60% of the peaks located within the promoter regions and the first intron. 195 and ii) a limited number of differential accessible regions identified between CAR^{High} T and 196 CAR^{Low} T (Fig. S5 and Table S2). Interestingly, these small transcriptomic and epigenomic 197 differences were enough to separate CAR^{High} T cells from CAR^{Low} T cells in a principal 198 components analysis in both CD4⁺ and CD8⁺ T cell subsets (Fig. 3A and S6). Interestingly, DEG 199 between CAR^{High} T and CAR^{Low} T cells were associated to genes involved in tonic signaling and 200 T cell activation (Fig. 3B and S6). These results corroborated our phenotypic observations (see 201 previous sections), where CAR^{High} T cells showed increased expression level of genes related to 202 lymphocyte activation, such as HLA-DR or CD74, and costimulatory molecules, as TNFRSF4 203 (OX40) and TNFRSF9 (4-1BB) (Fig. 3C and S6). Moreover, these results were consistent with the 204 results observed in Jurkat-TPR experiments (see section above). While reduced overlapping was 205 observed between DEGs and differential peaks, those genes showing differential expression and 206 chromatin accessibility were mainly related to the activation and tonic signaling, including HLA-207 DRA, CIITA, TNFRSF9 and CTLA-4 (Fig. 3D and S6). Together, these results suggest that small 208 differences in gene expression and chromatin accessibility associated to increased CAR levels can 209 210 substantially modify the overall phenotypic and functional profile of CAR T cells.

211 Single-cell sequencing reveals specific distribution of CAR^{High} T cells

212 To better understand the heterogeneity of CAR T cells and the influence of CAR level on their

transcriptomic profile, we performed single cell transcriptomic analysis on 43,981 CAR T cells from three independent productions. After quality control and filtering, we performed an integrated

²¹⁴ from three independent productions. After quality control and intering, we performed an integra

analysis and identified 23 clusters of CAR T cell subpopulations (Fig. S7). Clusters identified based 215 on cell cycle gene signatures, those containing high levels of mitochondrial genes, as well as 216 clusters lacking expression of T cell markers were excluded from further analysis (Fig. S7). Cell 217 types and functional states of the remaining 15 clusters (containing 28,117 cells with range of 218 7,416-10,5093 cells/donor) were defined according to the expression of previously described 219 canonical markers (26–28) (Fig. 4A-B). Within CD4⁺ cells we identified early memory (IL7R), 220 memory (TCF7, CCR7, CD27), activated (HLA-DRA, OX40), cytotoxic (GZMA, PRF1) and Th2 221 helper (GATA3) CAR T cells, with a minority of other subtypes including cells expressing genes 222 related to glycolysis and IFN response. Among CD8⁺ cells, we distinguished memory (TCF7, 223 CCR7) and cytotoxic (GZMA, PRF1, NKG7) CAR T cells. Furthermore, in accordance with the 224 phenotypical results, we identified a pre-exhausted cluster of CD8⁺ CAR T cells characterized by 225 the expression of cytotoxic genes along with inhibitory receptors, like LAG3 and TIGIT (33) (Fig. 226 4B-C). Analysis of V(D)J rearrangement showed a polyclonal diversity of CAR T cells within all 227 the clusters, indicating no specific enrichment of any particular clone (Table S3). 228

To robustly identify CAR T cells with high expression of the CAR construct in our single cell data, 229 we developed gene signatures associated to both CD4⁺ and CD8⁺ CAR^{High} T cells, using DEGs 230 from bulk RNA-seq analysis between CAR^{High} T and CAR^{Low} T cells (Table S4), as these 231 populations were sorted based on CAR protein expression (see methods). We found a better 232 233 correlation between the gene signature and CAR protein level, than the one observed between the expression of the CAR gene and its protein expression (Fig. S8). Moreover, the possibility to 234 extrapolate these gene signatures to other datasets was assessed via leave-one-out cross-validation 235 (Fig. S8). Then, we annotated CAR^{High} T cells in our single cell data using the developed signatures 236 (Fig. 5A), and we observed that CAR^{High} T cells mainly localized within activated CD4⁺ cells, 237 representing more than 50% of the cells in cluster 6 and almost 80% of the cells in cluster 17 (Fig. 238 5B). Furthermore, in the CD8⁺ T cell compartment, CAR^{High} T cells were more represented in 239 cluster 9 showing a pre-exhausted phenotype (Fig. 5B). These results are in accordance with our 240 previous phenotypic and transcriptomic analysis performed in sorted CAR^{High} T and CAR^{Low} T cell 241 populations, where CAR^{High} T cells were significantly enriched in activation and tonic signaling 242 signatures (Fig. 5C-D). Moreover, we perform this analysis using an independent single cell public 243

dataset of CAR T products targeting CD19 from patients with DLBCL (*26*), obtaining similar
results (Fig. S9). Altogether, our results would indicate a strong association between tonic
signaling, CAR T cell activation and cell exhaustion that is increased in CAR T cells with high
CAR density defined either by the gene signature or the protein expression.

248 CAR density is associated with differential activation of regulatory networks

To elucidate the molecular regulation of CAR^{High} T cells we applied SimiC (34), a novel GRN 249 inference algorithm for scRNA-seq data that imposes a similarity constraint when jointly inferring 250 the GRNs for each specific cell state. Based on this analysis, we observed regulons (a TF and its 251 associated target genes) that were similarly activated between CAR^{High} and the rest of the CAR T 252 cells (Fig. S10), such as regulons implicated in T cell differentiation (GATA3, RUNX3) and signal 253 transduction (STAT1, REL, RELA, JUN/AP1) (35-37). On the other hand, we identified some 254 regulons that were more active in CAR^{High} T cells, like STAT3, a TF associated with development 255 and maintenance of T cell memory (38), or ARID5A, a TF related to the control of the stability of 256 STAT3 (39) (Fig. S10) and other regulons that presented reduced activity in CAR^{High} T cells, like 257 BTG2, a TF related to the prevention of proliferation exacerbation and spontaneous activation (40)258 259 (Fig. S10). These changes in regulon activity could explain the increased central memory phenotype and also provide a regulatory mechanism for the increased activation observed in 260 CAR^{High} T cells. 261

Interestingly, we also observed regulons presenting a multimodal activation profile. To determine whether this distribution might be related to different activity between clusters, we computed the

distribution of the regulon activity in each cluster (provided it contain at least 5% of CARHigh T 264 cells) (Fig. S10). As an example, we observed that the activity of RFX5 regulon, a member of the 265 RFX family that interacts with HLA class II genes and promotes their transcription (41, 42), was 266 overexpressed in CD8⁺ CAR^{High} T cells, independently of the T cell subtype. However, RFX5 267 regulon activity progressively increased through CD8⁺ differentiation when we analyzed CD8⁺ 268 CAR T cells that were not CAR^{High} T, from memory, to cytotoxic and finally to pre-exhausted cells 269 (Fig. 6A). In addition, we searched for regulons that could explain the exhausted phenotype 270 observed in CAR^{High} T cells. We observed that NR4A1 and MAF regulons, already described as 271 drivers of T cell exhaustion (43–45), were more active in CAR^{High} T cells (Fig. 6A). On the other 272 hand, the SATB1 regulon, related to PD1 inhibition (46), presented lower activity in CAR^{High} T 273 cells (Fig. 6A). All these results may provide molecular mechanism underpinning the exhausted 274 phenotype observed in CAR^{High} T. Overall, our GRN analysis using SimiC provides mechanistic 275 insights into the regulatory networks behind the phenotypic and functional differences observed in 276 CAR^{High} T cells, identifying regulons that regulate T cell function previously described, supporting 277 the usefulness of this methodology. More importantly, the use of SimiC permits the generation of 278 novel hypothesis based on identified regulatory factors that could be modulated, ultimately to the 279 280 design of optimized CAR T therapies.

281 CAR^{High} T gene signature is associated with clinical response

Given the differences in functionality between CAR^{High} and CAR^{Low} T cells, we reasoned that CAR 282 density might have an impact on the clinical response to CAR T-cell therapies. To evaluate this 283 hypothesis, we applied the gene signatures associated with CAR^{High} T cells to infusion products 284 from several clinical trials with public transcriptomic data available (25, 26). We first applied our 285 CD4⁺ and CD8⁺ signatures to bulk RNA-seq data of 34 infusion products from adult CLL patients 286 287 treated with CTL019 (25). We observed that products from patients with poor clinical response (partial responders and non-responders) presented a significant higher score of both CD4⁺ and 288 CD8⁺ CAR^{High} T signatures (Fig. 7A). We also assessed CAR^{High} T signature on a single cell RNA-289 seq dataset comprising anti-CD19 CAR T infusion products from 24 patients with DLBCL (26). 290 291 We found that the products from non-responder patients were significantly enriched in CD8⁺ CAR^{High} T cells (Fig. 7B), supporting the correlation between CAR density and clinical response. 292 293 Finally, we examined the correlation between the clinical response and the expression of CAR measured by FACS, in the cell products of an academic clinical trial assessing ARI-0002h, a CAR 294 T cell targeting BCMA (CARTBCMA-HCB-01; NCT04309981). Patients with partial response 295 (less or equal than VGPR) showed an increase in the number of CAR^{High} T within the infusion 296 297 product versus the patients presenting sCR (Fig. 7C). Moreover, a shorter duration of response was observed in patients with increased percentage of CAR^{High} T cells (p=0.04, as continuous variable 298 in Cox regression model). No statistical correlation was observed with the development or grade 299 of cytokine release syndrome (CRS), although the patients of this cohort presented only low-grade 300 CRS (grades 1 and 2). Overall, our data suggest that CAR T therapeutic products enriched in T 301 cells with high CAR density on the membrane, would impact negatively on the clinical response. 302

304 **DISCUSSION**

The functionality of CAR T cells relies on the interaction between the tumor and engineered T cells 305 (1). However, as living drugs, CAR T cells are heterogeneous products in which intrinsic and 306 extrinsic factors can influence their functionality having a significant impact on their clinical 307 efficacy (8-16). Among others, the level of antigen expression has been associated with anti-tumor 308 response (8, 24). Our study contributes to identify new determinants of CAR T cell function 309 demonstrating a clear role of the level of CAR expression on the functionality of CAR T cells. Our 310 results indicate that high levels of CAR expression are associated with increased tonic signaling 311 and a cell exhausted phenotype, characterized by the expression of multiple inhibitory receptors, 312 such as PD1, CTLA4, LAG3, TIM3 and TIGIT, among others. This phenotype has been associated 313 to reduced responses and worse long-term relapse free survival (13, 25, 48), which is consistent 314 with our findings demonstrating decreased responses in patients with increased levels of CAR^{High} 315 316 T cells in different hematological malignancies.

- Previous studies have demonstrated that constitutive signaling induced by multiple factors related to the different CAR moieties (49, 50), are associated to early T cell exhaustion (17–20). For instance, a recent study has shown fundamental differences in CAR signaling between CAR T cells
- 320 with CD28 or CD8 transmembrane domains (TMD) related to the heterodimerization potential of
- 321 the different transmembrane domains (51). Our results indicated that an increased density of the
- 322 CAR molecule in the surface of the T cells (CAR^{High} T cells), triggered by a higher number of viral
- 323 integrations, could be enough to induce spontaneous clustering of the chimeric receptor molecules
- 324 leading to tonic signaling. Interestingly, tonic signaling was not restricted to CAR^{High} T cells
- targeting BCMA, since it was also observed in CAR^{High} T cells with different specificities (CD19,
- 326 CD33 and HER2), suggesting that this phenomenon was related to CAR density rather than CAR
- 327 specificity.

Most CAR T constructs are generated using retro/lentiviral vectors with strong promoters, like 328 human EF1a or the murine stem cell virus LTR (MSCV), with no physiological regulation. These 329 promoters induce high levels of CAR expression that can lead to tonic signaling and premature 330 exhaustion. The possibility of reducing gene expression via weaker promoters as well as through 331 more physiological promoters has been associated with decreased tonic signaling (22, 23, 52). In 332 fact, the use of the MND promoter has been shown to reduce CAR surface density, while EF1a 333 promoter increased its density, leading to a higher cytotoxic activity, cytokine production and 334 expression of exhaustion markers (23). Thus, the use of physiological promoters would be a 335 strategy to prevent an increase in CAR^{High} T cells, thus limiting exhaustion of CAR-T and favoring 336 long term persistence and antitumor efficacy (22). 337

The increased tonic signal and the concomitant basal activation of CAR^{High} T cells resulted in an 338 increase in tumor cytotoxicity in vitro. The higher cytotoxicity and cytokine production observed 339 in CAR^{High} T cells is also consistent with previous reports describing differences in antitumoral 340 efficacy due to increased ligand-independent signaling (32, 53). Nevertheless, the pre-exhausted 341 phenotype of CAR^{High} T cells could compromise their long-term persistence and function. Our 342 results from the *in vivo* experiments based on "stress tests" (32, 54) support this hypothesis, since 343 we observed reduced bone marrow infiltration of CAR^{High} T cells. However, the use of CAR^{Low} T 344 cells was not associated with improved survival of the animals since both CAR T populations were 345 able to induce strong antitumor responses. Unfortunately, the use of immunodeficient mouse 346 models is a significant limitation for testing CAR T cell efficacy, as well as toxicity. The use of 347 humanized mice, or syngeneic mouse models together with mouse CAR T cells, should help to 348 better characterize in vivo the impact of CAR expression of long-term efficacy of the different 349 products. Nevertheless, the clinical correlation between response and decrease number of CAR^{High} 350 T cells in the infusion product would also be consistent with the hypothesis that infusion of CAR^{High} 351

352 T cells could compromise their long-term persistence and function.

The avidity of the scFv against the antigen plays an important role on the functionality of the CAR T cells and its control may result in more effective therapies (*55*, *56*). Moreover, strategies combining the avidity of scFvs and the targeting of two molecules (or epitopes) may represent interesting approaches to increase the antitumoral efficacy and to reduce the toxicity (*57*, *58*). This would be particularly relevant for MM where, despite impressive initial responses, a significant number of patients experience a relapse after CAR T cell therapies (*5*, *6*). However, the impact that CAR density could play on these approaches using CAR T cells with strong avidity and/or targeting

360 several molecules, would be an additional aspect that should be further analyzed.

A relevant question faced in this work was the development of specific methodology for proper 361 identification of CAR^{High} T cells from transcriptomic data. We defined a molecular signature 362 associated with increased CAR density, for both CD4⁺ and CD8⁺ CAR T cells, that showed a higher 363 correlation with cell surface CAR levels that the RNA expression. The implications of these 364 signatures were severalfold: 1) this signature was key to annotate cells and identify clusters 365 enriched in CAR^{High} T cells; 2) in addition, these signatures allowed us to perform GRN analysis 366 using single cell data and identify key regulons associated to exhaustion of CAR T cells, such as 367 NR4A1 and MAF (43-45), that were differentially activated in CAR^{High} T cells, providing 368 mechanistic insights of the regulatory pathways driving the differences between CAR T cells with 369 different CAR density; 3) finally, the definition of the signature associated with CAR^{High} T cells 370 371 allowed us to apply the gene signature to transcriptomic data from CAR T cell products of patients undergoing CAR T treatment (25, 26), demonstrating a correlation between CAR expression and 372 response in several cohorts of patients with different diseases (CLL and DLBCL). In the case of 373 MM patients undergoing CAR T therapies, we also found a correlation between the CAR levels 374 present on the therapeutic products and both the depth of response and its duration. These 375 observations support our hypothesis that the presence of a high number of CAR^{High} T cells within 376 the products limits the efficacy of CAR T therapies and suggests that the application of our gene 377 signature may represent a new prognostic factor in patients treated with CAR T cells. 378 In summary, our data demonstrate that CAR density plays an important role in CAR T activity with 379

In summary, our data demonstrate that CAR density plays an important role in CAR T activity with an impact on clinical response. Moreover, the comprehension of regulatory mechanisms driven by CAR densities at the single cell level offers an important tool for the identification of key regulatory factors, that could be modulated for the development of improved therapies. Lastly, the application of a gene signature associated to increased CAR density, if validated in additional cohorts may represent a valuable tool for predicting responses in patients undergoing CAR T cell therapy.

386 MATERIALS AND METHODS

387 Cell lines

- 388 Jurkat-TPR (kindly provided by Dr. P. Steinberg; Medical University of Vienna), ARP-1-GFPLuc
- 389 (kindly provided by Dr. Epstein; University of Arkansas for Medical Sciences), U266, MOLP8,
- 390 K562 and K562-CD19 cells were cultured in RPMI 1640 supplemented with 10% FBS. MOLM13
- and MV411 were cultured in RPMI 1640 supplemented with 20% FBS. HEK293T and BT474 cells
- 392 were cultured in DMEM supplemented with 10% FBS. All media were supplemented with 1%
- ³⁹³ penicillin/streptomycin and 1% L-Glutamine. All cell lines were maintained at 37°C in 5% CO₂.

394 Lentiviral vector construction and virus preparation

- A third-generation self-inactivating lentiviral vector (pCCL) was used to express under the EF1a promoter a second-generation CAR constructs targeting BCMA (J22.9 clone from ARI-0002h), CD19 (FMC63 clone), CD33 (my96 clone) or HER2 (FRP5 clone). CAR structure comprised the single-chain variable fragment (scFv), a CD8 hinge and transmembrane domain, the 4-1BB and
- 399 CD3 ζ endodomains fused to a truncated version of the EGFR or a BFP reporter gene. Lentiviral
- 400 vectors were produced in HEK293T cells following standard procedures. Briefly, 6×10^6 cells were
- 401 co-transfected with LV vector along with pMDLg/pRRE (Gag/Pol), pRSVRev and pMD2.G
- 402 (VSVG envelope) packaging plasmid using Lipofectamine 2000 (Invitrogen). Supernatants were
- 403 collected 40h after transfection, filtered, concentrated using Lenti-X Concentrator (Takara)
- 404 following manufacturer specifications and stored at -80°C until use.

405 Analysis of CAR signaling in Jurkat-TPR

- 406 Jurkat-TPR cells, transduced at MOI of 1 with CARs targeting BCMA, CD33, CD19 or HER2,
- 407 were co-cultured in triplicate with ARP1-GFPLuc, MOLP8 and U266 cells for BCMA CARs,
- 408 MOLM13 and MV4-11 cells for CD33, K562-CD19 cells for CD19 CARs or BT474 cells for
- HER2 CARs, at a 1:1 effector to tumor cell ratio. Non-transduced Jurkat-TPR cells were used as
- 410 control. CAR^{High} and CAR^{Low} subpopulations were defined according to the fluorescence intensity
 411 (FI) using an EGFR-APC antibody (clone AY13, Biolegend). Thresholds for CAR^{High} and CAR^{Low}
- 411 (FI) using an EGFR-APC antibody (clone AY13, Biolegend). Thresholds for CAR^{High} and CAR^{Low} 412 were define as the top and bottom FI quartiles respectively (CAR^{High}: FI > 1.5×10^5 and CAR^{Low}:
- 412 were define as the top and bottom F1 quartnes respectively (CAR^{4- σ -}; F1 > 1.5x10⁻ and CAR^{4- σ -}; 413 FI < 2x10⁴). Activation of the NFAT, NF- κ B and AP-1 pathways was quantified before and 24h
- 413 after co-culture with tumor cells measuring eGFP, eCFP and mCherry emissions respectively,
- 415 using a CytoFLEX LX Flow Cytometer (Beckman Coulter) (Fig. S1).

416 **CAR T cell generation**

- 417 CD4⁺ and CD8⁺ cells were isolated from PBMCs using CD4 and CD8 MicroBeads (Miltenyi
- Biotec) in the AutoMACS Pro Separator (Miltenyi Biotec). Isolated T cells were activated with 10
- 419 μ l/ml T cell TransAct (Miltenyi Biotec) for 48h and infected with the CAR lentiviral vector at MOI
- 420 2 with 10 μ l/ml of LentiBoost (Sirion Biotech). CAR T cells were expanded in RPMI 1640 culture
- 421 medium supplemented with 3% human serum (Sigma), 1% penicillin/streptomycin and 625 IU/ml
- 422 of human IL-7 and 85 IU/ml of human IL-15 (Miltenyi Biotec). CAR T cells were counted, and
- the concentration was adjusted to 1×10^6 cells/ml every two days.

424 Flow cytometry and CAR^{High} and CAR^{Low} T cell isolation

- 425 Phenotypic characterization of T cells and CAR T cells was performed at day 0 and 13 of the
- 426 production, respectively. All antibodies were purchased from Biolegend unless otherwise stated
- 427 (Table S5). Data was acquired on a BD FACSCanto II (BD Biosciences) and analyzed using the
- 428 FlowJo Software version 10 (Tree Star). CAR^{High} and CAR^{Low} T cell subpopulations were sorted
- 429 according to the BFP FI. Thresholds for CAR^{High} and CAR^{Low} were define as the top and bottom
- 430 FI quartiles respectively (CAR^{High}: FI > $1.2x10^4$; CAR^{Low}: FI < $4x10^3$) (Fig. S3). All cells were
- 431 sorted using a MoFlo Astrios EQ (Beckman Coulter).

432

433 **Quantification of CAR density**

The number of CAR molecules on the surface of CAR T cell products from healthy donors and 434 MM patients was quantitated using Quantum Simply Cellular (QSC) (Bangs Laboratories, USA: 435 815), according to the manufacturer's protocol. This methodology allows the conversion of 436 fluorescence intensity value into absolute numbers of binding molecules using a calibration curve. 437 Data acquisition was performed on a BD FACSCanto II (BD Biosciences), and the results were 438 analyzed using FlowJo Software version 10 (Tree Star). A threshold of 5000 and 1500 molecules 439 was applied to define cells as CAR^{High} or CAR^{Low} respectively, since these were a lower bound 440 (5000 on CAR^{High}) and an upper bound (1500 on CAR^{Low}) on number of molecules present on the 441 samples sorted for functional and transcriptomic experiments. 442

443 Viral copy number

Viral copy number (VCN) per cell were determined by qPCR. Genomic DNA was extracted using
 the DNeasy Blood and Tissue Kit (Qiagen). VCN/cell were quantified by duplex detection of the

446 Psi sequence, normalized to ALBUMIN, using specific primers and detected with the TaqMan

447 probes (Table S6). qPCR was performed using the Absolute qPCR Mix Low ROX Mix (Thermo

- 448 Scientific) in a QuantStudioTM 3 Real-Time PCR System (Thermo Fisher Scientific). Results were
- analyzed in QuantStudio 3 Design and Analysis Software (Thermo Fisher Scientific).

450 Cytotoxicity assay and cytokine production

451 Cytotoxicity was determined using ARP1-GFPLuc as target tumor cells. Briefly, ARP1-GFPLuc

- 452 cells were cultured with CAR^{High} T and CAR^{Low} T cells at different ratios in RPMI 1640 culture
- 453 medium, supplemented with 3% human serum (Sigma) and 1% penicillin/streptomycin in Nunc[™]
- 454 96-Well Round Bottom plates (ThermoFisher Scientific). After 24h, luminescence measured using
- 455 the Bright-Glo[™] Luciferase Assay System (Promega) according to the manufacturer's
- 456 instructions. IFN γ , TNF α and IL-2 cytokine production was quantified using BDTM Immunoassay
- 457 ELISA reagents (BD Biosciences) following manufacturer protocol.

458 In vivo experiments

All experimental procedures were approved by the Ethics Committee of the University of Navarra 459 460 and the Institute of Public Health of Navarra according to European Council Guidelines. NOD-SCID-Il2rg^{-/-} (NSG) mice were purchased from The Jackson Laboratory (JAX) and bred and 461 maintained in-house in a pathogen-free facility. Eight-to-twelve-week-old male or female mice 462 were irradiated at 1.5 Gy at day -1 and 1×10^{6} ARP1-GFPLuc cells were intravenously injected 463 the following day. Mice were randomized to ensure equal pre-treatment tumor burden before CAR 464 T cell treatment. At day 6 mice received i.v. injection of 0.5×10⁶ either CAR^{High} T or CAR^{Low} T 465 cells. A subset of mice was sacrificed at day 28 to analyze the presence of cells in bone marrow. 466 Tumor progression was measured by bioluminescent imaging using the PhotonIMAGER 467 (Biospacelab). Signal was quantified using M3Vision Analysis Software (Biospacelab). Mice were 468 humanely euthanized when mice demonstrated signs of morbidity and/or hindlimb paralysis. 469

470 **RNA-sequencing and bioinformatics analysis**

471 RNA-seq was performed following MARS-seq protocol adapted for bulk RNA-seq (59, 60) with

472 minor modifications. RNA-seq libraries quantification was done with Qubit 3.0 Fluorometer (Life

473 Technologies) and size profiles were examined using Agilent's 4200 TapeStation System.

- 474 Libraries were sequenced in an Illumina NextSeq500 at a sequence depth of 10 million reads per
- 475 sample. Samples were aligned to the Human genome (GRCh38) with STAR (v2.6.1). Gene
- 476 expression was quantified with quant3p (github.com/ctlab/quant3p). Downstream analyses were
- 477 performed in R (v3.6.2). Data transformation, normalization, and differential gene expression

- 478 analysis were performed with DESeq2. T cell activation and tonic signaling gene signatures used
- 479 in this work were obtained from previous publications (25–28) (Table S7).

480 Assay for transposase-accessible chromatin (ATAC-seq) and bioinformatics analysis

Accessible chromatin mapping was performed using FAST-ATAC-seq (61) with minor 481 modifications. Libraries were quantified and their size profiles examined as described above. 482 Sequencing was carried out in an Illumina NextSeq500 at a depth of 20 million reads per sample. 483 ATAC-seq reads were aligned to the human genome (GRCh38) using Bowtie2 (v2.3.4). Peak 484 calling from each individual replicate was performed with MACS2 (v.2.1.0). Differential 485 accessible analysis was analyzed with Csaw R package. The consensus peak set was derived from 486 the union of all replicate peak sets for both conditions. For normalization, a non-linear LOESS-487 based (LOESS: Locally estimated scatterplot smoothing) method was applied. Differential 488 enrichment was analyzed using edgeR package. Finally, ChIPseeker R package was used for 489 annotation and visualization of genomics features. 490

491 Single cell RNA-sequencing (scRNA-seq)

scRNA-seq was performed in FACS-sorted CAR T cells (BFP⁺ cells) from three independent 492 donors using the Chromium Single Cell 5' Reagent Kit (10X Genomics) according to the 493 manufacturer's instructions. After quality control and quantification, single cell libraries were 494 sequenced at an average depth of at least 30000 reads/cell. 43,981 cells were analyzed, and 28,117 495 cells passed quality control with an average sequencing depth of 42,296 reads/cell, yielding an 496 average of 2,541 genes/cell. TCR α/β sequencing was performed with 10X Genomics Single Cell 497 V(D)J Immune Profiling Solution (10× Genomics). After quality control and quantification, single 498 cell V(D)J enriched libraries were pooled and sequenced at a minimum depth of 5000 reads per 499 cell. 500

scRNA-seq data were demultiplexed, aligned to the human reference (GRCh38) and the feature-501 barcode matrix was quantified using Cell Ranger (v6.0.1) from 10X Genomics. Further 502 computational analysis was performed using Seurat (v3.1.5). Cells were subjected to QC filters 503 504 based on the number of detected genes, number of UMIs and proportion of UMIs mapped to mitochondrial and ribosomal genes per cell. Each dataset was subjected to normalization, 505 identification of highly variable genes and removal of unwanted sources of variation. Integration 506 of all the dataset was based on Seurat's canonical correlation analysis. Unsupervised clustering 507 analysis with the resolution set to 0.8 yield a total of 23 cell clusters. Non-linear dimensional 508 reduction was performed using t-distributed stochastic neighbor embedding (t-SNE) and UMAP. 509 510 To describe the cell types and states defined by each cluster, we performed a manual review of the differentially expressed genes that were identified for each cell cluster by Seurat, using canonical 511 marker genes as reference. TCR reconstruction and paired TCR clonotype analysis was performed 512

513 using Cell Ranger v6.0.2 for V(D)J sequence assembly.

514 Generation of CAR^{High} signature

515 The CAR^{High} signature was generated using differentially expressed genes between CAR^{High} T and 516 CAR^{Low} T cell samples for each cell type (CD4⁺ and CD8⁺ cells). Specifically, the signature is 517 created as:

518
$$S = \sum_{i} \log(F_i) * z(\log(E_i + 0.5))$$

where F_i is the fold change of the gene *i* between the CAR^{High} T and CAR^{Low} T samples, z(.) is the function computing the z-score and E_i is the normalized gene expression for the *i*-th gene. This

signature takes the z-score of the logarithm of the expression gene, allowing to compare the genes

- between them, and multiplying it by the logarithm of the fold-change to imprint the directionality
- 523 of the signature gene.
- 524

525 Gene regulatory network analysis

526 Cells were labelled as CAR^{High} by applying the developed CAR^{High} signature. Then, using the most 527 variable 300 TFs and 3000 genes, SimiC was run with the default parameters across CAR^{High}-528 labelled cells and the rest. GRNs were plotted using the GRN incidence matrices provided by 529 SimiC. The histograms for the different regulons were computed from the 'Regulon Activity Score'

- 530 provided by SimiC. This score was also used to compute the regulatory dissimilarity score for the
- 531 selected cell clusters.

532 **Patient samples and clinical data**

533 Samples were obtained from patients with MM enrolled in the academic clinical trial 534 CARTBCMA-HCB-01 (NCT04309981), lead by Dr. Fernandez de Larrea (Hospital Clínic in 535 Barcelona), assessing the BCMA-CAR T ARI-0002h, developed at IDIBAPS/Hospital Clínic in

536 Barcelona. All subjects provided written informed consent. Clinical response was defined

- 537 according to the MM Response Criteria (62) as: Stringent Complete Response (sCR), Very Good
- 538 Partial Response (VGPR), Partial Response (PR) and Progressive Disease (PD). The CAR^{High}
- signature was applied to gene expression data publicly available (25, 26), which allowed us to: i)
- quantify the number of CAR^{High} T cells within $CD4^+$ and $CD8^+$ population in CAR T cell products
- 541 when scRNA-seq data was available; and ii) to score the CAR T cell products according to CD4⁺
- and $CD8^+ CAR^{High}$ signature when bulk RNA-seq data was available. The clinical data was judged
- the same way as in the original manuscript, grouping the different treatment responses into: Non Response (NR), Partial Response (PR), Partial Response with Transformed Disease (PRTD) and
- 544 Response (NR), Partial Response (PR), Partial Resp545 Complete Response (CR).

546 Statistical Analysis

- 547 Statistical analyses were performed using GraphPad Prism for Mac version 9.3.1. The different
- tests used in this work are indicated in the figure legend.

550 References

551		
552	1.	C. H. June, M. Sadelain, Chimeric antigen receptor therapy. New England Journal of Medicine. 379 (2018),
553		pp. 64–73.
554	2.	S. J. Schuster, M. R. Bishop, C. S. Tam, E. K. Waller, P. Borchmann, J. P. McGuirk, U. Jäger, S. Jaglowski,
555		C. Andreadis, J. R. Westin, I. Fleury, V. Bachanova, S. R. Foley, P. J. Ho, S. Mielke, J. M. Magenau, H.
556		Holte, S. Pantano, L. B. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. T. Maziarz, Tisagenlecleucel in
557		adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine. 380, 45-56
558		(2019).
559	3.	S. L. Maude, T. W. Laetsch, J. Buechner, S. Rives, M. Boyer, H. Bittencourt, P. Bader, M. R. Verneris, H. E.
560		Stefanski, G. D. Myers, M. Qayed, B. de Moerloose, H. Hiramatsu, K. Schlis, K. L. Davis, P. L. Martin, E.
561		R. Nemecek, G. A. Yanik, C. Peters, A. Baruchel, N. Boissel, F. Mechinaud, A. Balduzzi, J. Krueger, C. H.
562		June, B. L. Levine, P. Wood, T. Taran, M. Leung, K. T. Mueller, Y. Zhang, K. Sen, D. Lebwohl, M. A.
563		Pulsipher, S. A. Grupp, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia.
564		New England Journal of Medicine. 378 , 439–448 (2018).
565	4.	S. S. Neelapu, F. L. Locke, N. L. Bartlett, L. J. Lekakis, D. B. Miklos, C. A. Jacobson, I. Braunschweig, O.
566		O. Oluwole, T. Siddiqi, Y. Lin, J. M. Timmerman, P. J. Stiff, J. W. Friedberg, I. W. Flinn, A. Goy, B. T.
567		Hill, M. R. Smith, A. Deol, U. Farooq, P. McSweeney, J. Munoz, I. Avivi, J. E. Castro, J. R. Westin, J. C.
568		Chavez, A. Ghobadi, K. v. Komanduri, R. Levy, E. D. Jacobsen, T. E. Witzig, P. Reagan, A. Bot, J. Rossi, L.
569		Navale, Y. Jiang, J. Aycock, M. Elias, D. Chang, J. Wiezorek, W. Y. Go, Axicabtagene Ciloleucel CAR T-
570		Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> . 377 , 2531–2544
570		(2017).
572	5.	N. Raje, J. Berdeja, Y. Lin, D. Siegel, S. Jagannath, D. Madduri, M. Liedtke, J. Rosenblatt, M. v. Maus, A.
573	5.	Turka, LP. Lam, R. A. Morgan, K. Friedman, M. Massaro, J. Wang, G. Russotti, Z. Yang, T. Campbell, K.
574		Hege, F. Petrocca, M. T. Quigley, N. Munshi, J. N. Kochenderfer, Anti-BCMA CAR T-Cell Therapy bb2121
575		in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 380 , 1726–1737 (2019).
576	6.	N. C. Munshi, L. D. Anderson, N. Shah, D. Madduri, J. Berdeja, S. Lonial, N. Raje, Y. Lin, D. Siegel, A.
577	0.	Oriol, P. Moreau, I. Yakoub-Agha, M. Delforge, M. Cavo, H. Einsele, H. Goldschmidt, K. Weisel, A.
578		Rambaldi, D. Reece, F. Petrocca, M. Massaro, J. N. Connarn, S. Kaiser, P. Patel, L. Huang, T. B. Campbell,
579		K. Hege, J. San-Miguel, Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. <i>The New</i>
580		England journal of medicine. 384 , 705–716 (2021).
581	7.	J. G. Berdeja, D. Madduri, S. Z. Usmani, A. Jakubowiak, M. Agha, A. D. Cohen, A. K. Stewart, P. Hari, M.
582	/.	Htut, A. Lesokhin, A. Deol, N. C. Munshi, E. O'Donnell, D. Avigan, I. Singh, E. Zudaire, T. M. Yeh, A. J.
583		Allred, Y. Olyslager, A. Banerjee, C. C. Jackson, J. D. Goldberg, J. M. Schecter, W. Deraedt, S. H. Zhuang,
584		J. Infante, D. Geng, X. Wu, M. J. Carrasco-Alfonso, M. Akram, F. Hossain, S. Rizvi, F. Fan, Y. Lin, T.
585		Martin, S. Jagannath, Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen
586		receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase
587		1b/2 open-label study. <i>The Lancet</i> (2021), doi:10.1016/S0140-6736(21)00933-8.
588	8.	R. G. Majzner, S. P. Rietberg, E. Sotillo, R. Dong, V. T. Vachharajani, L. Labanieh, J. H. Myklebust, M.
589	0.	Kadapakkam, E. W. Weber, A. M. Tousley, R. M. Richards, S. Heitzeneder, S. M. Nguyen, V. Wiebking, J.
590		Theruvath, R. C. Lynn, P. Xu, A. R. Dunn, R. D. Vale, C. L. Mackall, Tuning the antigen density
590 591		requirement for car T-cell activity. <i>Cancer Discovery</i> . 10 , 702–723 (2020).
591 592	9.	F. L. Locke, J. M. Rossi, S. S. Neelapu, C. A. Jacobson, D. B. Miklos, A. Ghobadi, O. O. Oluwole, P. M.
592 593	9.	Reagan, L. J. Lekakis, Y. Lin, M. Sherman, M. Better, W. Y. Go, J. S. Wiezorek, A. Xue, A. Bot, Tumor
595 594		burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell
594 595		lymphoma. <i>Blood Advances</i> . 4 , 4898–4911 (2020).
595 596	10.	O. U. Kawalekar, R. S. O'Connor, J. A. Fraietta, L. Guo, S. E. McGettigan, A. D. Posey, P. R. Patel, S.
590 597	10.	Guedan, J. Scholler, B. Keith, N. Snyder, I. Blair, M. C. Milone, C. H. June, Distinct Signaling of
597 598		Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells.
598 599		<i>Immunity.</i> 44, 380–390 (2016).
600	11.	S. Guedan, A. D. Posey, C. Shaw, A. Wing, T. Da, P. R. Patel, S. E. McGettigan, V. Casado-Medrano, O. U.
	11.	
601 602		Kawalekar, M. Uribe-Herranz, D. Song, J. J. Melenhorst, S. F. Lacey, J. Scholler, B. Keith, R. M. Young, C. H. June, Enhancing CAP, T. cell persistence through ICOS and 4 1BR costimulation. <i>ICL insight</i> , 3 (2018)
		H. June, Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation. <i>JCI insight</i> . 3 (2018), doi:10.1172/ioi.insight.96076
603 604	12.	doi:10.1172/jci.insight.96976. L. Alabanza, M. Pegues, C. Geldres, V. Shi, J. J. W. Wiltzius, S. A. Sievers, S. Yang, J. N. Kochenderfer,
	12.	
605 606		Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinga and Transmembrane Demains, Malagular Theorem, 25 , 2452, 2465 (2017)
606 607	12	Hinge and Transmembrane Domains. <i>Molecular Therapy</i> . 25 , 2452–2465 (2017).
607 608	13.	A. L. Garfall, E. K. Dancy, A. D. Cohen, W. T. Hwang, J. A. Fraietta, M. M. Davis, B. L. Levine, D. L. Siagel, F. A. Stadtmauer, D. T. Vagl, A. Waxman, A. P. Panapart, M. C. Milana, C. H. Juna, I. J.
608 600		Siegel, E. A. Stadtmauer, D. T. Vogl, A. Waxman, A. P. Rapoport, M. C. Milone, C. H. June, J. J. Malanharat, T. coll phonotymes associated with effective CAP T coll thereave in postinduction vs released
609 610		Melenhorst, T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed
610		multiple myeloma. <i>Blood Advances</i> . 3 , 2812–2815 (2019).

611 612	14.	J. Rossi, P. Paczkowski, Y. W. Shen, K. Morse, B. Flynn, A. Kaiser, C. Ng, K. Gallatin, T. Cain, R. Fan, S. Mackay, J. R. Heath, S. A. Rosenberg, J. N. Kochenderfer, J. Zhou, A. Bot, Preinfusion polyfunctional anti-
613 614		CD19 chimeric antigen receptor T cells are associated with clinical outcomes in NHL. <i>Blood.</i> 132 , 804–814 (2018).
615	15.	C. J. Turtle, L. A. Hanafi, C. Berger, M. Hudecek, B. Pender, E. Robinson, R. Hawkins, C. Chaney, S.
616	101	Cherian, X. Chen, L. Soma, B. Wood, D. Li, S. Heimfeld, S. R. Riddell, D. G. Maloney, Immunotherapy of
617		non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-
618		modified T cells. Science Translational Medicine. 8 (2016),
619	1.6	doi:10.1097/CCM.0b013e31823da96d.Hydrogen.
620	16.	D. Sommermeyer, M. Hudecek, P. L. Kosasih, T. Gogishvili, D. G. Maloney, C. J. Turtle, S. R. Riddell,
621		Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior
622		antitumor reactivity in vivo (Nature Publishing Group, 2016; http://dx.doi.org/10.1038/leu.2015.247), vol.
623		30.
624	17.	A. H. Long, W. M. Haso, J. F. Shern, K. M. Wanhainen, M. Murgai, M. Ingaramo, J. P. Smith, A. J. Walker,
625		M. E. Kohler, V. R. Venkateshwara, R. N. Kaplan, G. H. Patterson, T. J. Fry, R. J. Orentas, C. L. Mackall, 4-
626		1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
627		Nature Medicine (2015), doi:10.1038/nm.3838.
628	18.	M. J. Frigault, J. Lee, M. C. Basil, C. Carpenito, S. Motohashi, J. Scholler, O. U. Kawalekar, S. Guedan, S.
629	10.	E. McGettigan, A. D. Posey, S. Ang, L. J. N. Cooper, J. M. Platt, F. B. Johnson, C. M. Paulos, Y. Zhao, M.
630		Kalos, M. C. Milone, C. H. June, Identification of chimeric antigen receptors that mediate constitutive or
631		inducible proliferation of T cells. <i>Cancer Immunology Research</i> . 3 , 356–367 (2015).
632	10	1 00 1
	19.	S. Sukumaran, N. Watanabe, P. Bajgain, K. Raja, S. Mohammed, W. E. Fisher, M. K. Brenner, A. M. Leen,
633		J. F. Vera, Enhancing the potency and specificity of engineered T cells for cancer treatment. <i>Cancer</i>
634	•	Discovery. 8, 972–987 (2018).
635	20.	D. Gomes-Silva, M. Mukherjee, M. Srinivasan, G. Krenciute, O. Dakhova, Y. Zheng, J. M. S. Cabral, C. M.
636		Rooney, J. S. Orange, M. K. Brenner, M. Mamonkin, Tonic 4-1BB Costimulation in Chimeric Antigen
637		Receptors Impedes T Cell Survival and Is Vector-Dependent. Cell Reports (2017),
638		doi:10.1016/j.celrep.2017.09.015.
639	21.	J. Eyquem, J. Mansilla-Soto, T. Giavridis, S. J. C. van der Stegen, M. Hamieh, K. M. Cunanan, A. Odak, M.
640		Gönen, M. Sadelain, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection.
641		<i>Nature</i> . 543 , 113–117 (2017).
642	22.	M. Tristán-Manzano, N. Maldonado-Pérez, P. Justicia-Lirio, P. Muñoz, M. Cortijo-Gutiérrez, K. Pavlovic,
643		R. Jiménez-Moreno, S. Nogueras, Md. Carmona, S. Sánchez-Hernández, A. Aguilar-González, M. Castella,
644		M. Juan, C. Marañón, K. Benabdellah, C. Herrera, F. Martin, medRxiv, in press (available at
645		http://medrxiv.org/content/early/2021/03/20/2021.03.17.21253300.abstract).
646	23.	J. Y. Ho, L. Wang, Y. Liu, M. Ba, J. Yang, X. Zhang, D. Chen, P. Lu, J. Li, Promoter usage regulating the
647		surface density of CAR molecules may modulate the kinetics of CAR-T cells in vivo. Molecular Therapy -
648		Methods and Clinical Development. 21, 237–246 (2021).
649	24.	A. J. Walker, R. G. Majzner, L. Zhang, K. Wanhainen, A. H. Long, S. M. Nguyen, P. Lopomo, M. Vigny, T.
650	2	J. Fry, R. J. Orentas, C. L. Mackall, Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric
651		Antigen Receptor Targeting Anaplastic Lymphoma Kinase. <i>Molecular Therapy</i> . 25 , 2189–2201 (2017).
652	25.	J. A. Fraietta, S. F. Lacey, E. J. Orlando, I. Pruteanu-Malinici, M. Gohil, S. Lundh, A. C. Boesteanu, Y.
653	23.	Wang, R. S. O'connor, W. T. Hwang, E. Pequignot, D. E. Ambrose, C. Zhang, N. Wilcox, F. Bedoya, C.
654		Dorfmeier, F. Chen, L. Tian, H. Parakandi, M. Gupta, R. M. Young, F. B. Johnson, I. Kulikovskaya, L. Liu,
655		J. Xu, S. H. Kassim, M. M. Davis, B. L. Levine, N. v. Frey, D. L. Siegel, A. C. Huang, E. J. Wherry, H.
656		Bitter, J. L. Brogdon, D. L. Porter, C. H. June, J. J. Melenhorst, Determinants of response and resistance to
657		CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. <i>Nature Medicine</i> .
658	26	24 , 563–571 (2018).
659	26.	Q. Deng, G. Han, N. Puebla-Osorio, M. C. J. Ma, P. Strati, B. Chasen, E. Dai, M. Dang, N. Jain, H. Yang, Y.
660		Wang, S. Zhang, R. Wang, R. Chen, J. Showell, S. Ghosh, S. Patchva, Q. Zhang, R. Sun, F. Hagemeister, L.
661		Fayad, F. Samaniego, H. C. Lee, L. J. Nastoupil, N. Fowler, R. Eric Davis, J. Westin, S. S. Neelapu, L.
662		Wang, M. R. Green, Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and
663		toxicity in patients with large B cell lymphomas. <i>Nature Medicine</i> (2020), doi:10.1038/s41591-020-1061-7.
664	27.	A. Sheih, V. Voillet, L. A. Hanafi, H. A. DeBerg, M. Yajima, R. Hawkins, V. Gersuk, S. R. Riddell, D. G.
665		Maloney, M. E. Wohlfahrt, D. Pande, M. R. Enstrom, H. P. Kiem, J. E. Adair, R. Gottardo, P. S. Linsley, C.
666		J. Turtle, Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing
667		CD19 CAR-T immunotherapy. Nature Communications. 11 (2020), doi:10.1038/s41467-019-13880-1.
668	28.	A. C. Boroughs, R. C. Larson, N. D. Marjanovic, K. Gosik, A. P. Castano, C. B. M. Porter, S. J. Lorrey, O.
669		Ashenberg, L. Jerby, M. Hofree, G. Smith-Rosario, R. Morris, J. Gould, L. S. Riley, T. R. Berger, S. J.
670		Riesenfeld, O. Rozenblatt-Rosen, B. D. Choi, A. Regev, M. v. Maus, A Distinct Transcriptional Program in

Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq. Molecular Therapy. 28 671 672 (2020), doi:10.1016/j.ymthe.2020.07.023. 673 29. G. M. Chen, C. Chen, R. K. Das, P. Gao, C. H. Chen, S. Bandyopadhyay, Y. Y. Ding, Y. Uzun, W. Yu, Q. 674 Zhu, R. M. Myers, S. A. Grupp, D. M. Barrett, K. Tan, Integrative bulk and single-cell profiling of 675 premanufacture t-cell populations reveals factors mediating long-term persistence of car t-cell therapy. 676 Cancer Discovery. 11, 2186–2199 (2021). Q. Zhang, H. Hu, S. Y. Chen, C. J. Liu, F. F. Hu, J. Yu, Y. Wu, A. Y. Guo, Transcriptome and Regulatory 677 30. Network Analyses of CD19-CAR-T Immunotherapy for B-ALL. Genomics, Proteomics and Bioinformatics. 678 679 17. 190–200 (2019). 680 31. S. Rosskopf, J. Leitner, W. Paster, L. T. Morton, R. S. Hagedoorn, P. Steinberger, M. H. M. Heemskerk, A 681 Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies. 682 Oncotarget. 9, 17608-17619 (2018). 683 32. J. Feucht, J. Sun, J. Eyquem, Y. J. Ho, Z. Zhao, J. Leibold, A. Dobrin, A. Cabriolu, M. Hamieh, M. Sadelain, 684 Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nature 685 Medicine. 25, 82-88 (2019). C. U. Blank, W. N. Haining, W. Held, P. G. Hogan, A. Kallies, E. Lugli, R. C. Lynn, M. Philip, A. Rao, N. 686 33. 687 P. Restifo, A. Schietinger, T. N. Schumacher, P. L. Schwartzberg, A. H. Sharpe, D. E. Speiser, E. J. Wherry, 688 B. A. Youngblood, D. Zehn, Defining 'T cell exhaustion.' Nature Reviews Immunology. 19, 665-674 (2019). 689 J. Peng, G. Serrano, I. M. Traniello, M. E. Calleja-Cervantes, U. v Chembazhi, S. Bangru, T. Ezponda, J. 34. 690 Roberto Rodriguez-Madoz, A. Kalsotra, F. Prosper, I. Ochoa, M. Hernaez, A single-cell gene regulatory 691 network inference method for identifying complex regulatory dynamics across cell phenotypes. *Bioarxiv*, 1– 692 31 (2021). 693 35. I. C. Ho, T. S. Tai, S. Y. Pai, GATA3 and the T-cell lineage: Essential functions before and after T-helper-2-694 cell differentiation. Nature Reviews Immunology. 9, 125-135 (2009). 695 D. Wang, H. Diao, A. J. Getzler, W. Rogal, M. A. Frederick, J. Milner, B. Yu, S. Crotty, A. W. Goldrath, M. 36. 696 E. Pipkin, The Transcription Factor Runx3 Establishes Chromatin Accessibility of cis-Regulatory Landscapes that Drive Memory Cytotoxic T Lymphocyte Formation. Immunity. 48, 659-674.e6 (2018). 697 698 G. Gaud, R. Lesourne, P. E. Love, Regulatory mechanisms in T cell receptor signalling. Nature Reviews 37. 699 Immunology. 18, 485–497 (2018). 700 38. A. M. Siegel, J. Heimall, A. F. Freeman, A. P. Hsu, E. Brittain, J. M. Brenchley, D. C. Douek, G. H. Fahle, J. 701 I. Cohen, S. M. Holland, J. D. Milner, A critical role for STAT3 transcription factor signaling in the 702 development and maintenance of human T cell memory. Immunity. 35, 806-818 (2011). 703 39. K. Masuda, B. Ripley, K. K. Nyati, P. K. Dubey, M. M. U. Zaman, H. Hanieh, M. Higa, K. Yamashita, D. 704 M. Standley, T. Mashima, M. Katahira, T. Okamoto, Y. Matsuura, O. Takeuchi, T. Kishimoto, Arid5a 705 regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA. Journal of Experimental 706 Medicine. 213, 605-619 (2016). 707 40. S. S. Hwang, J. Lim, Z. Yu, P. Kong, E. Sefik, H. Xu, C. C. D. Harman, L. K. Kim, G. R. Lee, H.-B. Li, R. 708 A. Flavell, mRNA destabilization by BTG1 and BTG2 maintains T cell quiescence. Science (2020), 709 doi:10.1126/science.aax0194. 710 41. J. Villard, M. Peretti, K. Masternak, E. Barras, G. Caretti, R. Mantovani, W. Reith, A Functionally Essential 711 Domain of RFX5 Mediates Activation of Major Histocompatibility Complex Class II Promoters by 712 Promoting Cooperative Binding between RFX and NF-Y. Molecular and Cellular Biology (2000). 713 doi:10.1128/mcb.20.10.3364-3376.2000. P. Rousseau, K. Masternak, M. Krawczyk, W. Reith, J. Dausset, E. D. Carosella, P. Moreau, In vivo, RFX5 714 42. 715 binds differently to the human leucocyte antigen-E, -F, and -G gene promoters and participates in HLA class 716 I protein expression in a cell type-dependent manner. Immunology (2004), doi:10.1111/j.1365-717 2567.2004.01783.x. 718 43. J. Chen, I. F. López-Moyado, H. Seo, C. W. J. Lio, L. J. Hempleman, T. Sekiya, A. Yoshimura, J. P. Scott-719 Browne, A. Rao, NR4A transcription factors limit CAR T cell function in solid tumours. Nature. 567, 530-720 534 (2019). 721 44. X. Liu, Y. Wang, H. Lu, J. Li, X. Yan, M. Xiao, J. Hao, A. Alekseev, H. Khong, T. Chen, R. Huang, J. Wu, 722 Q. Zhao, Q. Wu, S. Xu, X. Wang, W. Jin, S. Yu, Y. Wang, L. Wei, A. Wang, B. Zhong, L. Ni, X. Liu, R. 723 Nurieva, L. Ye, O. Tian, X. W. Bian, C. Dong, Genome-wide analysis identifies NR4A1 as a key mediator of T cell dysfunction. Nature. 567, 525-529 (2019). 724 725 M. Giordano, C. Henin, J. Maurizio, C. Imbratta, P. Bourdely, M. Buferne, L. Baitsch, L. Vanhille, M. H. 45. 726 Sieweke, D. E. Speiser, N. Auphan-Anezin, A. Schmitt-Verhulst, G. Verdeil, Molecular profiling of CD 8 T 727 cells in autochthonous melanoma identifies Maf as driver of exhaustion . The EMBO Journal. 34, 2042-2058 728 (2015). 729 46. T. L. Stephen, K. K. Payne, R. A. Chaurio, M. J. Allegrezza, H. Zhu, J. Perez-Sanz, A. Perales-Puchalt, J. M. 730 Nguyen, A. E. Vara-Ailor, E. B. Eruslanov, M. E. Borowsky, R. Zhang, T. M. Laufer, J. R. Conejo-Garcia,

731 SATB1 Expression Governs Epigenetic Repression of PD-1 in Tumor-Reactive T Cells. Immunity (2017), 732 doi:10.1016/j.immuni.2016.12.015. 733 47. R. G. Majzner, C. L. Mackall, Tumor antigen escape from car t-cell therapy. *Cancer Discovery* (2018), 734 doi:10.1158/2159-8290.CD-18-0442. 735 48. N. W. C. J. van de Donk, M. Themeli, S. Z. Usmani, Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. 2, 302-318 (2021). 736 49. J. Javaraman, M. P. Mellody, A. J. Hou, R. P. Desai, A. W. Fung, A. H. T. Pham, Y. Y. Chen, W. Zhao, 737 CAR-T design: Elements and their synergistic function. *EBioMedicine*. 58 (2020), 738 739 doi:10.1016/j.ebiom.2020.102931. 740 50. A. Ajina, J. Maher, Strategies to address chimeric antigen receptor tonic signaling. Molecular Cancer 741 Therapeutics (2018), , doi:10.1158/1535-7163.MCT-17-1097. 742 51. Y. D. Muller, D. P. Nguyen, L. M. R. Ferreira, P. Ho, C. Raffin, R. V. B. Valencia, Z. Congrave-Wilson, T. 743 L. Roth, J. Eyquem, F. van Gool, A. Marson, L. Perez, J. A. Wells, J. A. Bluestone, Q. Tang, The CD28-744 Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28. Frontiers in 745 Immunology (2021), doi:10.3389/fimmu.2021.639818. 746 52. S. M. A. H. Rad, A. Poudel, G. M. Y. Tan, A. D. McLellan, Promoter choice: Who should drive the CAR in 747 T cells? PLoS ONE. 15, 1-18 (2020). 748 53. S. Guedan, A. Madar, V. Casado-Medrano, C. Shaw, A. Wing, F. Liu, R. M. Young, C. H. June, A. D. 749 Posey, Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor 750 durability. Journal of Clinical Investigation. 130, 3087-3097 (2020). 751 54. J. Eyquem, J. Mansilla-Soto, T. Giavridis, S. J. C. Van Der Stegen, M. Hamieh, K. M. Cunanan, A. Odak, 752 M. Gönen, M. Sadelain, Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 543, 113-117 (2017). 753 754 55. R. Greenman, Y. Pizem, M. Haus-Cohen, A. Goor, G. Horev, G. Denkberg, K. Sinik, Y. Elbaz, V. Bronner, 755 A. G. Levin, G. Horn, S. Shen-Orr, Y. Reiter, Shaping functional avidity of CAR T Cells: Affinity, avidity, 756 and antigen density that regulate response. Molecular Cancer Therapeutics. 20, 872-884 (2021). B. Salzer, C. M. Schueller, C. U. Zajc, T. Peters, M. A. Schoeber, B. Kovacic, M. C. Buri, E. Lobner, O. 757 56. Dushek, J. B. Huppa, C. Obinger, E. M. Putz, W. Holter, M. W. Traxlmayr, M. Lehner, Engineering 758 759 AvidCARs for combinatorial antigen recognition and reversible control of CAR function. Nature 760 Communications. 11, 1–16 (2020). 761 57. C. Fernández de Larrea, M. Staehr, A. v. Lopez, K. Y. Ng, Y. Chen, W. D. Godfrey, T. J. Purdon, V. 762 Ponomarev, H.-G. Wendel, R. J. Brentjens, E. L. Smith, Defining an Optimal Dual-Targeted CAR T-cell 763 Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven 764 Relapse in Multiple Myeloma. Blood Cancer Discovery. 1, 146-154 (2020). 765 58. J. G. Berdeja, D. Madduri, S. Z. Usmani, I. Singh, E. Zudaire, T.-M. Yeh, A. J. Allred, Y. Olyslager, A. 766 Banerjee, J. D. Goldberg, J. Schecter, D. Geng, X. Wu, M. Carrasco-Alfonso, S. Rizvi, F. (Xiaohu) Fan, A. 767 J. Jakubowiak, S. Jagannath, Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell 768 maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. Journal 769 of Clinical Oncology (2020), doi:10.1200/ico.2020.38.15 suppl.8505. 770 59. D. A. Jaitin, E. Kenigsberg, H. Keren-Shaul, N. Elefant, F. Paul, I. Zaretsky, A. Mildner, N. Cohen, S. Jung, 771 A. Tanay, I. Amit, Massively parallel single-cell RNA-seq for marker-free decomposition of tissues into cell 772 types. Science (2014), doi:10.1126/science.1247651. 773 60. Y. Lavin, S. Kobayashi, A. Leader, E. ad D. Amir, N. Elefant, C. Bigenwald, R. Remark, R. Sweeney, C. D. 774 Becker, J. H. Levine, K. Meinhof, A. Chow, S. Kim-Shulze, A. Wolf, C. Medaglia, H. Li, J. A. Rytlewski, R. 775 O. Emerson, A. Solovyov, B. D. Greenbaum, C. Sanders, M. Vignali, M. B. Beasley, R. Flores, S. Gnjatic, 776 D. Pe'er, A. Rahman, I. Amit, M. Merad, Innate Immune Landscape in Early Lung Adenocarcinoma by 777 Paired Single-Cell Analyses. Cell (2017), doi:10.1016/j.cell.2017.04.014. 778 61. M. R. Corces, J. D. Buenrostro, B. Wu, P. G. Greenside, S. M. Chan, J. L. Koenig, M. P. Snyder, J. K. 779 Pritchard, A. Kundaje, W. J. Greenleaf, R. Majeti, H. Y. Chang, Lineage-specific and single-cell chromatin 780 accessibility charts human hematopoiesis and leukemia evolution. Nature Genetics (2016), 781 doi:10.1038/ng.3646. 782 62. B. G. M. Durie, J. L. Harousseau, J. S. Miguel, J. Bladé, B. Barlogie, K. Anderson, M. Gertz, M. Dimopoulos, J. Westin, P. Sonneveld, H. Ludwig, G. Gahrton, M. Beksac, J. Crowley, A. Belch, M. 783 Boccadaro, M. Cavo, I. Turesson, D. Joshua, D. Vesole, R. Kyle, G. Tricot, R. Alexanian, M. Attal, G. 784 785 Merlini, R. Powles, P. Richardson, K. Shimizu, P. Tosi, S. v. Rajkumar, G. Morgan, International uniform 786 response criteria for multiple myeloma. Leukemia. 20, 1467–1473 (2006). 787 788

789 Acknowledgments

We thank the members of Hematology and Cell Therapy Department of the Clinica Universidad de Navarra for input throughout the course of the project and all the patients as well as families who made this study possible. We particularly acknowledge the patients for their participation in the Clinical trial CARTBCMA-HCB-01 (NCT04309981) and the Biobank of the University of Navarra for its collaboration.

795

796 Funding

797 This study was supported by the Instituto de Salud Carlos III co-financed by European Regional Development Fund-FEDER "A way to make Europe" (PI19/00669, ICI19/00025 and 798 ICI19/00069). Red de Terapia Celular TERCEL (RD16/0011/0005). Redes de Investigación 799 Cooperativa Orientada a Resultados en Salud RICORS (RD21/0017/0009 and RD21/0017/0019). 800 Centro de Investigación Biomédica en Red de Cáncer CIBERONC (CB16/12/00369 and 801 CB16/12/00489). Ministerio de Ciencia e Innovación co-financed by European Regional 802 Development Fund-FEDER "A way to make Europe" (RTC-2017-6578-1 and PID2019-803 108989RB-I00.). European Commission (H2020-JTI-IMI2-2019-18: Contract 945393; SC1-PM-804 08-2017: Contract 754658; and H2020-MSCA-IF-2019: Grant Agreement 898356). Gobierno de 805 Navarra (AGATA: 0011-1411-2020-000011 and 0011-1411-2020-000010; DESCARTHeS: 0011-806 1411-2019-000079 and 0011-1411-2019-000072; alloCART-LMA: PC011-012). Fundacion La 807 Caixa (CP042702). Asociacion Española Contra el Cáncer-AECC (LABAE21971FERN). Paula 808 and Rodger Riney Foundation. Paula Rodriguez-Marquez was supported by FPU grant 809 (FPU19/06160) from Ministerio de Universidades. 810

811

812 Author contributions

813 P.R-M., M.E.C-C., G.S, M.H., J.R.R-M., and F.P. designed the experiments. P.R-M., M.E.C-C.,

814 G.S, A.M-M. and C.C. conducted the experiments. P.R-M., M.E.C-C., G.S, A.O-C., M.H. and

J.R.R-M. performed the data analysis. M.L.P-B., P.R-O., A.A. and J.S-M. provided clinical advice.

816 A.O-C., M.E-R., C.C., M.C.V., M.R. M.P., M.J., A.U., C.F-L. and B.P. provided clinical samples

and data. T.L., J.J.L., B.P., M.H., J.R.R-M., and F.P discussed the study design and the results.

- 818 P.S-M., A.V-Z., S.R-D., R.M-T. and D.A. provided technical assistance. M.H., J.R.R-M., and F.P.
- 819 were responsible for research supervision, coordination, and strategy. P.R-M. and J.R.R-M. drafted
- 820 the manuscript. J.J.L., J.S-M., C.F-L., M.H., J.R.R-M., and F.P. reviewed and edited the

821 manuscript. All authors reviewed and approved the final version of the manuscript.

822

823 **Competing interests**

824 Authors declare that they have no competing interests.

825

826 Data and materials availability

827 All data needed to evaluate the conclusions in the paper are present in the paper and/or the

828 Supplementary Materials. The RNA-seq, ATAC-seq, and scRNA-seq data generated in this study

829 have been deposited in the GEO database (GEO#) and will be available upon publication.

Additional data related to this paper may be requested from the authors.

832 Figures and Tables

833

Fig. 1. CAR^{High} T cells present increased in vitro antitumoral efficacy and exhausted 834 phenotype. An *in vitro* functional and phenotypic characterization was performed on CAR T cells 835 targeting BCMA presenting different densities of the CAR molecule. (A) Schematic representation 836 of the procedure. CAR T cells were sorted into CAR^{High} and CAR^{Low} subpopulations via BFP 837 expression. Analyses were performed at basal state or after stimulation with tumor cells expressing 838 BCMA. (B) Quantification of the cytotoxic activity of CAR^{High} T and CAR^{Low} T cells against 839 ARP1-GFPLuc at different E:T ratio. The percentage of specific lysis (average of three technical 840 replicates) for each CAR T cell production (n=6) is depicted. (C) Quantification of IFN γ , IL-2 and 841 TNFα levels in supernatants from cytotoxic assays (ratio 0.5:1) measured by ELISA. The cytokine 842 concentration (pg/ml; average of three technical replicates) for each CAR T cell production (n=6) 843 is depicted. (D) Cytotoxic activity of ARI-0002h CAR T products from CARTBCMA-HCB-01 844 clinical trial, according to their enrichment in CAR^{High} T cells. (E) Analysis of the phenotype of 845 CAR^{High} and CAR^{Low} T cell populations before (basal n=10) and after stimulation (Stim n=5) with 846 ARP1-GFPLuc tumor cells. Mean ± SEM of each T cell subpopulation within CAR^{High} T and 847 CAR^{Low} T cells from is depicted. T_N : naïve; T_{SCM} : stem central memory; T_{CM} : central memory; 848 T_{EM}: effector memory; T_E: effector. Analysis of the expression of HLA-DR (F), CD137 (G) and a 849 combination of >2 exhaustion markers (LAG3, TIM3 and/or PD1) (H), in CAR^{High} T and CAR^{Low} 850 T cells before (basal n=10) and after stimulation (Stim n=5) with ARP1-GFPLuc tumor cells. 851 Wilcoxon test for paired samples (B and C), Mann-Whitney test (D), and 2-way ANOVA with 852 Sidak's multiple comparison(F-H). *p<0.05; **p<0.01; ***p<0.001. 853

854

Fig. 2. In vivo antitumoral efficacy of CAR T cells with different CAR densities. (A) Schematic 855 representation of the experimental procedure. NGS mice were injected intravenously (i.v.) on day 856 0 with 1x10⁶ ARP1GFPLuc cells/animal. After 6 days 0.5x10⁶ CAR^{High} T or CAR^{Low} T cells were 857 injected i.v. Bioluminiscence analysis (BLI) was performed on days 14, 35 and 49. Animal survival 858 was monitored until the end of the experiment (day 67). On day 28 a subset of animals was 859 sacrificed to analyze the presence of tumor and CAR T cells. (B) BLI images at the indicated days 860 of control mice (n=4) or treated with CAR^{High} T cells (n6) or CAR^{Low} T cells (n=6). (C) 861 Quantification of BLI (ph/s/cm²/sr) as a measurement of tumor growth. (D) Quantification of the 862 tumor cells present in the bone marrow (BM) of control mice (n=3) or treated with CAR^{High} T cells 863 (n=6) or CAR^{Low} T cells (n=6) at day 28 after CAR T cell administration. (E) Survival of control 864 mice (n=4) or treated with CAR^{High} T cells (n=6) or CAR^{Low} T cells (n=6). (F) Quantification of 865 the CAR T cells present in the BM of animals treated with CAR^{High} T cells (n=6) or CAR^{Low} T 866 cells (n=6) at day 28 after CAR T cell administration. Kruskall-Wallis test (D), Mantel-Cox (Long-867 Rank) test (E), and Mann-Whitney test (E). ns: not significant; *p<0.05. 868

869

Fig. 3. Transcriptomic profile and chromatin landscape of CD8⁺ CAR^{High} T cells. The 870 transcriptomic and epigenetic landscape of sorted CD8⁺ and CD4⁺ (see Fig. S6) CAR^{High} and 871 CAR^{Low} T cells (n=6) were profiled using high-throughput RNA sequencing (RNA-seq) and assay 872 for transposase-accessible chromatin (ATAC-seq). (A) RNA-seq and ATAC-seq principal 873 components (PC) analysis, corrected by patient heterogeneity, of sorted CD8⁺ CAR T cell subsets. 874 Percentage of variance explained by PC1 and PC2 are depicted. (B) Heatmap of differentially 875 expressed genes (DEGs) between CD8⁺ CAR^{High} T and CAR^{Low} T cells associated to genes 876 involved in tonic signaling and T cell activation. (C) Quantification of HLA-DR, CD74, TNFRSF4 877 (OX40) and TNFRSF9 (4-1BB) gene expression in CD8⁺ CAR^{High} T and CAR^{Low} T cells. (D) 878 UCSC genome browser tracks of CTLA-4, HLA-DRA, CIITA and TNFRSF9 showing differential 879

- peaks from ATAC-seq analysis between $CD8^+ CAR^{High} T$ and $CAR^{Low} T$ cells. Wilcoxon test for paired samples (C). *p<0.05.
- 882

Fig. 4. Characterization of CAR T cells at single cell level. CAR⁺ (BFP⁺) cells from three 883 independent CAR T cell productions were assayed by single-cell RNA sequencing. (A) An 884 overview of the 28,117 cells that passed QC and filtering for subsequent analyses in this study. 885 UMAP plot showing the 15 clusters that were analyzed. (B) Heatmap showing signature genes of 886 each cluster and putative assignments to cell types according to canonical marker genes. (C) 887 UMAP plot overlaid with mRNA expression of T cell markers (CD4 and CD8A), memory markers 888 (TCF7 and CCR7), activation markers (HLA-DRA and GATA3), effector enzymes (GZMA and 889 PRF1) and exhaustion markers (LAG3 and TIGIT). 890

891

Fig. 5. Single-cell sequencing reveals specific distribution of CAR^{High} T cells. Annotation and 892 further analysis of CAR^{High} T in the single cell data was performed by applying the gene signatures, 893 developed in this work, associated to both CD4⁺ and CD8⁺ CAR^{High} T cells, that showed higher 894 correlation with the CAR protein level than that yielded by the CAR gene expression. (A) UMAP 895 plot showing CAR^{High} T cell distribution across analyzed cells. (B) Quantification of the percentage 896 897 of CAR^{High} T cell along the different clusters. In accordance with phenotypic results, CAR^{High} T cells are mainly localized within activated CD4⁺ cells (cluster 6 and 17) and pre-exhausted CD8⁺ 898 T cells (cluster 9). (C) UMAP plots overlaid with the score of activation and tonic signaling 899 signatures, showing their distribution across cells. CAR^{High} T cells were enriched in the score for 900 both signatures. (D) Quantification of the signature score in CAR^{High} T cells from clusters 6 (CD4⁺ 901 activated), 8 (CD8⁺ cytotoxic) and 9 (CD8⁺ pre-exhausted), in comparison with the rest of the cells, 902 for both activation and tonic signaling signatures. CAR^{High} T cells presented a significant increase 903

- for both signatures in almost all three clusters analyzed. Wilcoxon test (D). ***p<0.001.
- 905

Fig. 6. CAR density is associated with differential activation of regulatory networks. 906 Dynamics in Gene Regulatory Networks (GRN) of CAR^{High} T cells were analyzed by SimiC, a 907 novel GRN inference algorithm for scRNA-seq data that imposes a similarity constraint when 908 jointly inferring the GRNs for each specific cell state. Histograms showing the activity score during 909 CD8⁺ T cell differentiation in CAR^{High} T cells versus the rest of the cells (A), and the inferred gene 910 network (B), of regulons RFX5, NR4A1, MAF and SATB1, Regulon activity of RFX5, a member 911 912 of the RFX family that interacts with HLA class II genes and promotes their transcription, and NR4A1 and MAF, that have been described as drivers of T cell exhaustion, was already high in 913 CAR^{High} T cells, independently of the phenotype, meanwhile in the rest of the cells, their activity 914 progressively increased, from CD8⁺ memory (cluster 3), to CD8⁺ cytotoxic (cluster 8) and finally 915 916 to CD8⁺ pre-exhausted (cluster 9) phenotypes. In contrast activity of SATB1 regulon, related to PD1 inhibition, was reduced in CAR^{High} T cells. 917


918


Fig. 7. Increased CAR levels negatively impact clinical response of CAR T therapies. To 919 920 evaluate the impact of increased CAR density on the clinical response, we quantify the presence of CAR^{High} T cells in the infusion products of several clinical trials. (A) The gene signatures 921 developed in this works, associated to CD4⁺ and CD8⁺ CAR^{High} T cells, were applied to 34 infusion 922 products from adult CLL patients treated with CTL019. Signature score for each CAR T cell 923 product is represented for both CD4⁺ (left) and CD8⁺ (right) gene signatures, in patients divided 924 according to clinical response into CR/PRTD (Complete Response/Partial Response with 925 Transformed Disease) and PR/NP (Partial Response/Non Response). Products from patients with 926


poor clinical response (PR/NR) presented a significant higher score of both CAR^{High} T signatures. 927 (B) Our gene signature was applied to available single cell RNA-seq dataset from 24 CAR T 928 infusion products from adult DLBCL patients treated with axi-cel. Percentage of CD8⁺ CAR^{High} T 929 present for each CAR T cell product is represented in patients divided according to clinical 930 response as described in (A). Products from PR/NR patients were significantly enriched in CD8⁺ 931 CAR^{High} T cells. (C) The number of CAR molecules/cell in 25 anti-BCMA CAR T infusion 932 products from CARTBCMA-HCB-01 clinical trial was quantified by FACS. CAR^{High} T cells were 933 defined as these cells with >5000 molecules/cell (see methods). Percentage of CAR^{High} T cells for 934 each infusion product is represented in patients divided into sCR (Stringent Complete Response) 935 and VGPR/PR (Very Good Partial Response/Partial Response) according to clinical response. 936 Patients with sCR showed a significantly decreased number of CAR^{High} T cells. Unpaired t tests 937 (A-C). *p<0.05; ***p<0.001. 938

940	Supplementary Materials
941	
942	Supplementary material for this article includes:
943	
944	Extended Material and Methods
945	Fig. S1. CAR density influences CAR-mediated signaling.
946	Fig. S2. In vitro characterization of CAR T cells targeting BCMA.
947	Fig. S3. Characterization of CAR T cells with different CAR densities.
948	Fig. S4. Phenotypic characterization of CAR T cells with different CAR densities.
949	Fig. S5. Epigenetic characterization of CAR ^{High} T and CAR ^{Low} T cells.
950	Fig. S6. Transcriptomic profile and chromatin landscape of CD4 ⁺ CAR ^{High} T cells.
951	Fig. S7. Characterization of CAR T cells at single cell level.
952	Fig. S8. Generation and characterization of gene signatures associated to CAR ^{High} T cells.
953	Fig. S9. Characterization of CAR ^{High} T cells at single cell level.
954	Fig. S10. Analysis of GRNs in cell with different CAR densities.
955 956	Table S1. List of differentially expressed genes in RNA-seq analysis between $CAR^{High} T$ and $CAR^{Low} T$ cells in both $CD4^+$ and $CD8^+$ cell subsets.
957 958	Table S2. List of differential peaks in ATAC-seq analysis between CAR^{High} T and CAR^{Low} T cells in both CD4 ⁺ and CD8 ⁺ cell subsets.
959	Table S3. List of VDJ clonotypes detected in scRNA-seq analysis of CAR T cells.
960	Table S4. List of the genes used for the generation of the signatures for CD4 ⁺ and CD8 ⁺
961	CAR ^{High} T cells.
962	Table S5. List of the antibodies used in this study.
963	Table S6. List of the primer and probe sequences used in this study.
964	Table S7. List of the genes used in the T cell activation and tonic signaling signatures.
965	


(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license .








(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.




(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license.



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuit It is made available under a CC-BY-NC-ND 4.0 International license .

FIGURE 6





Α *** *** 100-100-CD4⁺ CAR^{High} T CD8⁺ CAR^{High} T signature score signature score 0 0 -100 -100 -200 -200 -300 -300 CR/PRTD PR/NR (n=8) (n=26) CR/PRTD PR/NR (n=8) (n=26) В * 40-100 ns % CD8⁺ CAR^{High} T cells CAR^{High} T cells 80 30 % CD4⁺ 60 20 40 10 20 0 0 CR/PRTD PR/NR (n=9) (n=14) CR/PRTD PR/NR (n=8) (n=15) С 150 % CAR^{High} T cells 100 50 0 sCR VGPR/PR (n=15) (n=10)